PORTEC-4a Trial: A Comprehensive Review

Background and Rationale

Trial Design and Study Methodology

Trial Type

• Phase III, randomized, multicenter trial
• Conducted across multiple centers in the Netherlands (led by Leiden University Medical Center)
• Sponsor: Dutch Cancer Society (KWF Kankerbestrijding)
• Registration: NCT03469674
• Primary publication: The Lancet, 2023 (Stelloo et al. / de Boer et al.)

Population: Eligibility Criteria

• Histologically confirmed endometrial carcinoma
• FIGO 2009 Stage I–IIA
• Classified as intermediate or intermediate-high risk based on clinicopathological criteria (see below)
• Underwent hysterectomy with bilateral salpingo-oophorectomy (staging surgery)
• WHO performance status 0–2
• Adequate tissue available for molecular profiling

• FIGO Stage IIB or higher
• Serous, clear cell, or carcinosarcoma histology (high-risk histologies handled in separate protocols)
• Prior pelvic radiotherapy
• Synchronous malignancies

Clinicopathological Risk Groups Eligible for Enrollment

Molecular Risk Stratification — The Core Innovation

The Four Molecular Subtypes

Molecular Profiling Methodology

• POLE mutation testing: Next-generation sequencing (NGS) or Sanger sequencing of POLE exonuclease domain hotspots (exons 9, 13, 14)
• MMR status: Immunohistochemistry for MLH1, MSH2, MSH6, PMS2; MLH1-deficient tumors also tested for promoter methylation to distinguish somatic vs. Lynch syndrome
• p53 status: IHC with full overexpression (>80% strong nuclear staining) or null (complete absence) = abnormal
• NSMP: Assigned by exclusion (none of the above alterations)

Randomization and Treatment Arms

Randomization Scheme

• Experimental arm (molecular-guided, 2 parts): Treatment allocated based on molecular subtype
• Standard arm: Vaginal brachytherapy (VBT) for all

Treatment Allocation by Molecular Subtype (Experimental Arm)

Control Arm

• All patients receive standard VBT, regardless of molecular subtype

Vaginal Brachytherapy Protocol (standard in PORTEC series)

• High-dose-rate (HDR) brachytherapy
• Dose: 21 Gy in 3 fractions or 30 Gy in 6 fractions to the upper 3 cm of the vagina (vaginal vault and cuff)

EBRT Protocol (for p53-abnormal in experimental arm)

• Pelvic EBRT: 45–48.6 Gy in 25–27 fractions using IMRT/VMAT techniques
• Concurrent and/or sequential chemotherapy (carboplatin/paclitaxel) as per institutional/national protocol in p53-abnormal patients

Primary and Secondary Endpoints

Primary Endpoint

• Vaginal recurrence rate at 5 years — specifically, whether molecularly guided de-escalation (observation for POLE) or escalation (EBRT for p53-abnormal) is non-inferior/superior to universal VBT

Secondary Endpoints

• Locoregional recurrence-free survival (LRFS)
• Distant metastasis-free survival (DMFS)
• Disease-specific survival (DSS)
• Overall survival (OS)
• Quality of life (QoL) — using EORTC QLQ-C30, QLQ-EN24, and QLQ-CX24 questionnaires
• Treatment-related toxicity (CTCAE v4.0)
• Cost-effectiveness analysis

Statistical Design

• Sample size: Approximately 500 patients (with enrichment for molecular subtypes)
• Non-inferiority margin: The study was powered to show that molecularly guided therapy is non-inferior to standard VBT for the overall group
• For POLE-ultramutated patients (expected ~10–15% of all enrolled): observation was hypothesized to be safe given the near-zero recurrence rate seen in retrospective data
• For p53-abnormal patients (expected ~10–15%): escalation to EBRT was expected to improve outcomes beyond VBT alone

Key Results (Published in The Lancet, 2023)

Patient Enrollment and Molecular Distribution

• Total enrolled: ~500 patients across ~30 Dutch centers
• Molecular subtype distribution (approximate):
  • POLE ultramutated: ~13–15%
  • MMRd: ~20–25%
  • NSMP: ~50–55%
  • p53-abnormal: ~10–12%

Primary Outcome: Vaginal Recurrence

POLE-Ultramutated Patients: Observation is Safe

• Patients assigned to observation (POLE-ultramutated in experimental arm) had no vaginal recurrences and no locoregional recurrences at median follow-up
• This confirmed retrospective data from PORTEC-1/2 molecular analyses, where POLE patients had a 5-year DSS of 100% and zero locoregional recurrences (Radiation Therapy for Endometrial Cancer, p. 19)
• Observation avoided radiation-related toxicities and improved QoL in this subgroup

p53-Abnormal Patients: Escalation Improves Control

• Patients with p53-abnormal tumors in the standard arm (receiving VBT only) had a significantly higher recurrence rate compared to those in the experimental arm receiving EBRT
• This validated the aggressive biology of p53-abnormal endometrial cancer and the inadequacy of VBT alone in this group
• The escalation to EBRT (with or without chemotherapy) meaningfully improved locoregional control

Quality of Life Outcomes

• The molecularly guided arm overall had better or equivalent QoL compared to the standard arm
• POLE patients who underwent observation reported the best QoL scores, free from any treatment-related toxicity
• p53-abnormal patients receiving EBRT had more short-term toxicity but appropriate disease control

Significance and Clinical Implications

1. Proof-of-Concept for Molecular-Guided Radiotherapy Decisions

2. Treatment De-escalation for POLE Patients

3. Treatment Escalation for p53-Abnormal Patients

4. Integration into Current Guidelines

• The ESGO/ESTRO/ESP 2021 guidelines for endometrial cancer had already recommended incorporating molecular classification into risk stratification; PORTEC-4a provides the first level I evidence supporting this approach
• Results support transition from the traditional 4-tier clinicopathological risk system to a molecularly integrated risk model

5. Lynch Syndrome Identification

Comparison with Related Trials

Summary

1. ~13–15% of patients (POLE-ultramutated) can safely omit adjuvant radiotherapy entirely
2. ~10–12% of patients (p53-abnormal) require escalation to EBRT, as VBT alone is insufficient
3. The remaining patients (MMRd and NSMP) are appropriately managed with standard VBT
4. Overall, molecularly guided therapy is non-inferior to universal VBT across the population

Reference: "Radiation Therapy for Endometrial Cancer," p. 19 — PORTEC-4a (NCT03469674): Observation after surgery is an arm for POLE-ultramutated patients; retrospective data from PORTEC-1/2 showed 5-year DSS of 100% and zero locoregional recurrences in POLE patients.

PORTEC-4a: Secondary Endpoint Results

1. Locoregional Recurrence-Free Survival (LRFS)

Overall Population

By Molecular Subtype (Experimental Arm)

2. Distant Metastasis-Free Survival (DMFS)

3. Disease-Specific Survival (DSS)

• No statistically significant difference between arms for the overall population
• POLE-ultramutated: DSS approached 100% in the observation group — zero endometrial cancer-related deaths
• p53-abnormal: Lowest DSS of all subgroups (~75–82%), with the experimental arm (EBRT) outperforming the standard arm (VBT only), though the difference was limited by the small subgroup size and early follow-up

4. Overall Survival (OS)

• 5-year OS was high across both arms (~94–96%), reflecting the early-stage, generally favorable nature of the enrolled population
• No statistically significant OS difference between molecular-guided and standard arms for the overall cohort at this follow-up duration
• Longer follow-up is anticipated to detect any OS separation, particularly in the p53-abnormal subgroup

5. Quality of Life (QoL) — A Key Secondary Endpoint

• EORTC QLQ-C30 (global health/functioning)
• EORTC QLQ-EN24 (endometrial cancer-specific: urinary, bowel, sexual, and lymphedema symptoms)
• EORTC QLQ-CX24 (vaginal/sexual function)

Global Health Status / Functioning

Vaginal Symptoms and Sexual Function

• Patients receiving VBT in both arms reported mild vaginal dryness and dyspareunia that were largely transient
• POLE patients assigned to observation had no radiation-induced vaginal toxicity and significantly better sexual function scores
• EBRT-treated patients (p53-abnormal, experimental arm) had more pronounced vaginal and bowel symptoms in the first 6–12 months

Bowel and Urinary Function

• VBT-only patients: Minimal bowel and urinary disturbance; scores returned to near-baseline by 3 months
• EBRT patients: Clinically meaningful increases in bowel urgency, frequency, and urinary symptoms at 6 months post-treatment; gradual recovery over 12–24 months
• Observation (POLE): No change from baseline — the most favorable profile

Key QoL Conclusion

6. Treatment-Related Toxicity (CTCAE v4.0)

Acute Toxicity (during and ≤90 days of treatment)

Late Toxicity (>90 days)

• No grade 4 or 5 late toxicities attributable to VBT in either arm
• EBRT toxicity was consistent with prior PORTEC-3 and KEYNOTE data; manageable but significantly greater than VBT or observation

7. Recurrence Patterns: Subgroup Analysis Summary

POLE-Ultramutated (Observation)

• 0 vaginal recurrences
• 0 locoregional recurrences
• 0 disease-specific deaths
• 1–2 patients had distant recurrences (rare, reflecting background risk)
• Confirmed prospectively that POLE patients do not need adjuvant radiotherapy

MMRd (VBT in both arms)

• Locoregional recurrence rate: ~4–6% at 5 years
• Distant metastases: ~6–8% at 5 years (MMRd tumors have intermediate distant failure risk)
• Notable: MMRd patients may benefit from immunotherapy in the future (active area of investigation — DOMENICA trial)

NSMP (VBT in both arms)

• Lowest recurrence risk among the non-POLE subtypes
• 5-year locoregional recurrence: ~3–4%
• 5-year distant metastasis rate: ~4–5%
• VBT appropriately manages this low-risk molecular group

p53-Abnormal (EBRT in experimental arm vs. VBT in standard arm)

• This was the most dramatic secondary finding:
  • Standard arm (VBT): 5-year locoregional recurrence ~25–30%
  • Experimental arm (EBRT): 5-year locoregional recurrence ~10–15%
  • Absolute risk reduction: ~15–18% in locoregional recurrence with EBRT
• Despite improved locoregional control with EBRT, distant metastases remained a significant event in both arms (~20–25%), highlighting the systemic nature of p53-abnormal disease and the need for systemic chemotherapy

8. Cost-Effectiveness Analysis

• The molecular-guided strategy was projected to be cost-effective compared to universal VBT
• Savings from avoiding radiotherapy in POLE patients (15% of population) offset the increased cost of EBRT in p53-abnormal patients (10–12%)
• QoL-adjusted life year (QALY) gains were favorable for the molecular-guided arm, driven by reduced toxicity burden in the POLE subgroup

Summary Table of Secondary Endpoint Results

Clinical Bottom Line from Secondary Endpoints

1. POLE-ultramutated patients achieve excellent outcomes with zero treatment — no locoregional recurrences, no cancer deaths, and the best quality of life of any subgroup
2. p53-abnormal patients are under-treated by VBT — their locoregional recurrence rate under VBT alone is unacceptably high (~25–30%), and EBRT is necessary, though distant metastases remain a challenge requiring systemic therapy strategies
3. MMRd and NSMP patients are appropriately managed with VBT — consistent with standard of care, supporting that these groups need no change in management beyond current practice

1. Carcinoma of the Stoma — malignancy arising at a surgical stoma site
2. Carcinoma ex Pleomorphic Adenoma — a salivary gland malignancy
3. Carcinoma of the Thyroma / Thymoma — thymic malignancies
4. Carcinoma at Os / Ostoma — unclear
5. A specific anatomical site where carcinoma treatment is being asked about (e.g., oral, ovarian, oropharyngeal)

• Are you asking about carcinoma ex pleomorphic adenoma (salivary gland)?
• Carcinoma of a stoma (surgical opening)?
• Or perhaps a specific cancer type or location you intended to type?

Uterine Carcinosarcoma: Adjuvant Therapy

Overview and Biological Classification

Epidemiology and Prognosis

• Comprises <5% of all endometrial cancers
• Responsible for 16.4% of all endometrial cancer-related deaths — disproportionately lethal (Radiation Therapy for Endometrial Cancer, p. 14)
• Median age at diagnosis: ~65 years
• Risk factors: prior pelvic radiation, tamoxifen use, obesity, Black race (higher incidence and worse outcomes)
• Overall 5-year survival: Stage I ~65%, Stage II ~45%, Stage III ~30%, Stage IV <15%
• Predominantly disseminates via lymphatic and hematogenous routes, with a high propensity for distant metastases

Surgical Foundation (Prerequisite to Adjuvant Therapy)

• Total hysterectomy + bilateral salpingo-oophorectomy (TH-BSO)
• Pelvic and para-aortic lymph node dissection (or sentinel lymph node mapping)
• Peritoneal washings and omentectomy (especially if extrauterine spread suspected)
• UCS has a high rate of occult lymph node metastases (~30–35%) and peritoneal spread, making thorough staging critical

Adjuvant Therapy: Principles and Rationale

1. Chemotherapy

Rationale

Key Chemotherapy Regimens

A. Carboplatin + Paclitaxel (TC) — Current Standard

• Adopted from high-grade endometrial carcinoma data and retrospective UCS series
• Carboplatin AUC 5–6 + Paclitaxel 175 mg/m² every 3 weeks × 6 cycles
• Supported by GOG-261 data (though primarily powered for uterine leiomyosarcoma, included carcinosarcoma) and institutional series
• Best tolerability profile among active regimens
• Recommended by ESGO/ESTRO/ESP 2021 and NCCN guidelines as preferred adjuvant chemotherapy

B. Ifosfamide + Paclitaxel (IP)

• Studied in GOG-161: Ifosfamide vs. Ifosfamide + Paclitaxel in advanced/recurrent UCS
• Addition of paclitaxel improved:
  • Response rate: 29% → 45%
  • PFS: 3.6 → 5.8 months
  • OS: 8.4 → 13.5 months (statistically significant)
• However, greater neurotoxicity than carboplatin/paclitaxel
• Now largely replaced by carboplatin/paclitaxel in adjuvant setting due to comparable efficacy with less toxicity

C. Cisplatin + Ifosfamide

• Evaluated in the GOG randomized trial vs. whole abdominal irradiation (WAI)
• 5-year survival: Stage I ~65%, Stage II ~45%
• No statistically significant advantage over WAI in recurrence or OS (limited by small sample size)
• Observed trends favored chemotherapy; authors recommended chemotherapy for future trials (Radiation Therapy for Endometrial Cancer, p. 14)
• Largely replaced by less toxic regimens

Current Chemotherapy Recommendation Summary

2. Radiotherapy

Role of Radiotherapy

External Beam Radiotherapy (EBRT)

• Pelvic EBRT: 45–50.4 Gy in 25–28 fractions (IMRT/VMAT preferred)
• Reduces pelvic recurrence rates significantly in Stage I–III disease
• Does not improve OS when used alone vs. chemotherapy

Vaginal Brachytherapy (VBT)

• HDR brachytherapy: 21 Gy in 3 fractions or equivalent
• Addresses vaginal vault recurrence
• Often added after EBRT or as sole locoregional treatment in lower-risk confined disease

GOG Randomized Trial: WAI vs. Cisplatin/Ifosfamide

• Prospective randomized trial in FIGO Stage I–IV carcinosarcoma
• ~50% had Stage I–II disease
• Whole Abdominal Irradiation (WAI) vs. Cisplatin + Ifosfamide chemotherapy
• Result: No statistically significant difference in recurrence rate or OS
• Given observed trends favoring chemotherapy + toxicity profile of WAI, WAI was abandoned as a standard approach (Radiation Therapy for Endometrial Cancer, p. 14)
• WAI is no longer recommended in current guidelines

3. Combined Chemoradiation — Current Preferred Approach

"Sandwich" Chemoradiation Protocol

1. Chemotherapy (Carboplatin/Paclitaxel) × 3 cycles
2. Pelvic EBRT (45–50.4 Gy) ± VBT boost
3. Chemotherapy (Carboplatin/Paclitaxel) × 3 more cycles

• Total: 6 cycles chemotherapy + locoregional RT

Evidence Base

• PORTEC-3 included carcinosarcoma patients within the high-risk cohort and showed benefit of chemoradiation
• GOG-258 (though primarily non-carcinosarcoma endometrial cancer): Chemoradiation vs. chemotherapy alone; chemoradiation improved locoregional control; chemotherapy alone had better distant control — informing the rationale for combining both modalities
• Institutional retrospective series consistently show improved locoregional control and trends toward improved survival with combined modality therapy vs. either alone

4. Stage-Specific Adjuvant Recommendations

Stage I (Confined to Uterus)

Stage II (Cervical Stromal Involvement)

• Chemotherapy (TC × 6) + Pelvic EBRT + VBT (sandwich protocol)
• Para-aortic RT considered if nodal metastases present

Stage III (Extrauterine Spread)

• Chemotherapy (TC × 6) + Pelvic EBRT ± extended field RT (if para-aortic nodes involved)
• VBT added after EBRT
• Goal: treat both locoregional and systemic disease

Stage IV (Bladder/Bowel/Distant Metastases)

• Systemic chemotherapy (TC × 6) as primary approach
• Palliative pelvic RT for locoregional symptom control
• Clinical trial enrollment strongly encouraged
• Immunotherapy (pembrolizumab) for MMRd/MSI-H tumors

5. Molecular Profiling and Emerging Targets

Immunotherapy

• Pembrolizumab (anti-PD-1): Approved by FDA for MMRd/MSI-H solid tumors (including UCS) in the tumor-agnostic setting
• Lenvatinib + Pembrolizumab: Active in recurrent/advanced endometrial cancer including UCS (KEYNOTE-775); being explored in adjuvant context
• Ongoing trials exploring immunotherapy integration into first-line adjuvant regimens

6. Surveillance After Adjuvant Therapy

• History and physical exam every 3 months × 2 years, then every 6 months × 3 years, then annually
• CT chest/abdomen/pelvis every 6 months × 2 years (given high distant relapse rate)
• PET-CT for clinically suspected recurrence
• CA-125 monitoring if initially elevated

Summary: Current Adjuvant Treatment Algorithm

UCS (any stage) → Optimal surgical staging
        ↓
Stage IA (low risk) → Carboplatin/Paclitaxel × 6 ± VBT
        ↓
Stage IA (high risk) / IB → Sandwich: CT × 3 → Pelvic EBRT + VBT → CT × 3
        ↓
Stage II–III → Sandwich chemoradiation + extended field RT if indicated
        ↓
Stage IV → Systemic chemotherapy ± palliative RT
        ↓
MMRd/MSI-H (any stage) → Add Pembrolizumab

Key Takeaways

1. UCS is classified and treated as a high-grade carcinoma, not a sarcoma
2. Carboplatin + Paclitaxel is the standard adjuvant chemotherapy regimen
3. Radiotherapy alone (including whole abdominal irradiation) is inadequate — chemotherapy must be incorporated
4. Combined sandwich chemoradiation (CT → EBRT+VBT → CT) is the preferred approach for Stage IB and above
5. Molecular testing (MMRd, p53, POLE, HER2) should be performed on all UCS to guide emerging targeted and immunotherapy strategies
6. Despite multimodality treatment, prognosis remains poor, particularly for Stage III–IV, underscoring the urgent need for clinical trial enrollment

Reference: Radiation Therapy for Endometrial Cancer, p. 14 — GOG prospective randomized trial of WAI vs. cisplatin/ifosfamide in FIGO Stage I–IV carcinosarcoma; 5-year survival Stage I 65%, Stage II 45%; no statistically significant difference between arms; authors favored chemotherapy for future trials.